IDXX - Idexx Laboratories, Inc Stock Analysis
Idexx Laboratories, Inc (IDXX) is a publicly traded company listed on the NASD. It operates in the Diagnostics & Research industry, part of the broader Healthcare sector. The company has a market capitalization of 51.80B, generates annual revenue of 4.30B, and reports net income of 1.06B. As of the latest data, the stock is trading at 648.73 USD.
From a valuation and risk perspective, the stock presents the following profile: The stock is trading at a high valuation compared to the market average, suggesting investor optimism or growth expectations. The PEG ratio is above 2, which could imply the stock is overvalued based on its growth outlook. The company maintains a healthy balance between debt and equity, which is typical for stable businesses. This stock does not currently pay a dividend. The stock exhibits higher volatility than the market, which may indicate greater risk and potential reward.
Analyst recommendation stands at Buy (4.05), indicating current market sentiment. Institutional ownership is reported at 92.56%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of 39.89%, trading within a 52-week range of 356.14 - 769.98.
IDXX - Idexx Laboratories, Inc
648.73
Analyst Consensus
Buy 4.05
IDXX – Analyst Rating Summary
- Strong Buy: 7
- Buy: 9
- Hold: 6
- Sell: 0
- Strong Sell: 0
- Total Analysts: 22
| Index: | NDX, S&P 500 | P/E: | 49.61 | EPS (ttm): | 13.08 | Insider Own: | 1.10% | Shs Outstand: | 79.85M | Perf Week: | 0.90% |
| Market Cap: | 51.80B | Forward P/E: | 39.44 | EPS next Y: | 16.45 | Insider Trans: | -3.30% | Shs Float: | 78.97M | Perf Month: | -10.49% |
| Income(ttm): | 1.06B | PEG: | 3.09 | EPS next Q: | 3.43 | Inst Own: | 92.56% | Short Float: | 2.30% | Perf Quarter: | -8.58% |
| Revenue(ttm): | 4.30B | P/S: | 12.04 | EPS this Y: | 11.18% | Inst Trans: | -2.03% | Short Ratio: | 3.33 | Perf Half Y: | -0.54% |
| Book/sh: | 19.52 | P/B: | 33.24 | EPS next Y: | 13.11% | ROA: | 31.89% | Short Interest: | 1.81M | Perf Year: | 39.89% |
| Cash/sh: | 2.26 | P/C: | 287.68 | EPS next 5Y: | 12.75% | ROE: | 66.20% | 52W Range: | 356.14 - 769.98 | Perf YTD: | -4.11% |
| Dividend Est.: | - | P/FCF: | 49.00 | EPS past 3/5Y: | 17.67% 14.29% | ROIC: | 53.50% | 52W High: | 769.98 -15.75% | Beta: | 1.66 |
| Dividend TTM: | - | Quick Ratio: | 0.90 | Sales past 3/5Y: | 8.52% 9.72% | Gross Margin: | 64.38% | 52W Low: | 356.14 82.16% | Perf 5Y: | 22.76% |
| Dividend Ex-Date: | - | Current Ratio: | 1.23 | EPS Y/Y TTM: | 22.38% | Oper. Margin: | 31.71% | RSI (14): | 37.73 | Volatility: | 2.19% 2.41% |
| Employees: | 11000 | Debt/Eq: | 0.53 | Sales Y/Y TTM: | 10.42% | Profit Margin: | 24.62% | Recom: | 1.94 | Target Price: | 774.92 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.23 | EPS Q/Q: | 17.61% | Payout: | 0.00% | Rel Volume: | 0.74 | Prev Close: | 646.53 |
| Sales Surprise: | 1.67% | EPS Surprise: | 5.00% | Sales Q/Q: | 14.28% | Earnings: | Feb 02 BMO | Avg Volume: | 543.61K | Price: | 648.73 |
| SMA20: | -3.69% | SMA50: | -6.10% | SMA200: | 4.74% | Undervalued: 19.45% | Volume: | 400,085 | Change: | 0.34% | |
Graham Classic formula value: 399.34
(P/E=8 * 1g) Min value: 243.72
(current P/E * 2g) Max value: 882.19
Average value: 508.42
About Idexx Laboratories, Inc
IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.